| http://www.w3.org/ns/prov#value | - The company plans to develop ApitopesTM for other chronic diseases including Type I diabetes, rheumatoid arthritis and the common allergies.The unique Apitope peptides function as tolerogens, exerting their therapeutic effect via an highly selective immune re-balancing process that, in pre-clinical studies, has been linked to the induction of IL-10 secreting regulatory T cells.From the abstract of
|
